Anzeige
Mehr »
Login
Donnerstag, 30.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die neuen Aktien-Stars der nächsten Rallye-Stufe im Uransektor
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFQB | ISIN: US9840156023 | Ticker-Symbol: 3XB0
München
30.05.24
08:11 Uhr
3,560 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XENETIC BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
XENETIC BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur XENETIC BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Xenetic Biosciences appoints James Parslow as interim CEO1
22.05.Xenetic Biosciences, Inc. Announces Executive Leadership Transition274Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company")...
► Artikel lesen
22.05.Xenetic Biosciences, Inc. - 8-K, Current Report1
10.05.Xenetic Biosciences reports Q1 results1
10.05.Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update276Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of...
► Artikel lesen
10.05.Xenetic Biosciences, Inc. - 8-K, Current Report2
09.05.Xenetic Biosciences, Inc. - 10-Q, Quarterly Report1
26.04.Xenetic Biosciences, Inc. - 10-K/A, Annual Report1
22.03.Xenetic Dips on Full-Year Results2
22.03.Xenetic Biosciences reports FY results2
22.03.Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results373Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with...
► Artikel lesen
22.03.Xenetic Biosciences, Inc. - 8-K, Current Report1
21.03.Xenetic Biosciences Inc reports results for the quarter ended in December - Earnings Summary-
21.03.Xenetic Biosciences, Inc. - 10-K, Annual Report1
13.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 51.013The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS87166L2097 SYNLOGIC...
► Artikel lesen
12.02.Xenetic Biosciences, Inc. - 8-K, Current Report1
18.01.Xenetic to advance DNase programme with UVA partnership2
17.01.Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform518- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc....
► Artikel lesen
08.12.23Xenetic Biosciences, Inc. - 8-K, Current Report2
10.11.23Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results396Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platformDriving development towards Phase 1 program for the treatment of pancreatic carcinoma...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1